| Literature DB >> 30008599 |
Ping-Ching Wu1,2,3, Wen-Li Hsu4, Chun-Lin Chen5,6, Chen-Fuh Lam7, Yaw-Bin Huang6,8, Chien-Chi Huang9, Ming-Hong Lin10,11, Ming-Wei Lin6,12.
Abstract
Morphine is the most effective drugs for attenuating various types of severe pain, but morphine abuse carries a high risk of systemic fibrosis. Our previous have indicated that systemic administration of morphine hinders angiogenesis and delays wound healing. Here we have explained the pathological mechanism underlying the effect of morphine on wound healing. To determine how morphine affects wound healing, we first created a wound in mice treated them with a combination of a low doses (5 mg/kg/day) and high doses (20 or 30 mg/kg/day) of morphine. An In vivo study revealed that high-dose morphine-induced abnormal myofibroblasts persist after the end of wound healing because of connexin 43 (Cx43) upregulation. High-dose morphine-induced Cx43 increased the expression levels of focal adhesion molecules, namely fibronectin and alpha-smooth muscle actin (α-SMA) through the activation of transforming growth factor (TGF)-β1 signaling. In addition, we found that Cx43 contributed to TGF-βRII/ Smad2/3 signaling for regulating the differentiation of fibroblasts into myofibroblasts during high-dose morphine exposure. In conclusion, the abnormal regulation of Cx43 by morphine may induce systemic fibrosis because of abnormal myofibroblast function.Entities:
Keywords: Cx43; Fibrosis; Morphine; Wound Healing
Mesh:
Substances:
Year: 2018 PMID: 30008599 PMCID: PMC6036091 DOI: 10.7150/ijms.23074
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Fig 1Morphine increased the expressions of Cx43 and focal adhesion markers Western blot analysis for expressions of (A) Cx43, and α-SMA obtained from the wound tissue homogenates isolated from the control and morphine-treated (5 and 20 mg/kg/day) mice. Expression levels of Cx43 and α-SMA were quantified as shown in (B) and (C) respectively. (*, p < 0.05) (D) Expression levels of S100A4 and fibronectin were obtained from the control and morphine-treated (30 mg/kg/day) mice. Wound tissues were obtained on day 14 after creation of incisional wound. The expressions of S100A4 and fibronectin were quantified and are shown in (E) and (F), respectively. (**, p < 0.01; ***, p < 0.001)
Fig 2Myofibroblasts persisted after the end of wound healing in high-dose morphine treated mice. Wound tissues were obtained from the control and morphine-treated (30 mg/kg/day) mice on day 14 after creation of incisional wounds. Immunofluorescence staining in the wound tissue of (A) control group and (B) morphine-treated group; Cx43 and S100A4 exhibited conjugated green fluorescence and red fluorescence, respectively, which were co-localized and merged with yellow color in skin tissue after morphine treatment. The boxed region is magnified in the merged region arrows indicate the position of myofibroblasts.
Fig 3High-dose morphine stimulated α-SMA expression levels depending on Cx43 expression levels. Treatment of WS-1 cells with morphine increased the expression levels of (A) Cx43 and (B) fibronectin. (C) Morphine (10-4 μM)-induced Cx43 expression was reversed by naloxone (N, 10-4 μM). (D) Knockdown of Cx43 expression attenuated mRNA levels of Cx43, α-SMA and fibronectin in the WS-1 cells.
Fig 4High-dose morphine induced differentiation of fibroblasts to myofibroblasts through activation of the TGF-βRII/ Smad2/3 signaling pathway. (A) Morphine (10-4 μM) elicited differentiation of fibroblasts into myofibroblasts after 3 days of treatment; TGF-β1-induced myofibroblasts were used as a positive control. (B) Quantification of differentiation of fibroblasts into myofibroblasts in (A); naloxone significantly reduced the number of myofibroblasts differentiated because of morphine. (***, p < 0.001) (C) Immunofluorescence analysis exhibited high-dose morphine-induced expressions and distribution of Cx43 (red) and α-SMA (green), which were restrained through treatment with naloxone. (D) Morphine increased TGF-β receptor type-II (TGF-βR II) and phospho-Smad2/3 (p-Smad2/3) expression levels in a dose dependent manner.